# OSE Immunotherapeutics

Source: https://onco.cc/companies/ose-immunotherapeutics/  
OnCo record `ose-immunotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OSE Immunotherapeutics develops immune treatments for cancer and inflammatory disease. Its lead cancer product is an off-the-shelf vaccine for lung cancer patients whose immunotherapy has stopped working, now in a late-stage trial.

## Summary

OSE Immunotherapeutics SA (Euronext Paris: OSE), based in Nantes, is a clinical-stage company with platforms in immuno-oncology and immuno-inflammation. Tedopi (OSE2101) is an off-the-shelf neo-epitope T cell vaccine for HLA-A2 positive patients, in the phase 3 ARTEMIA trial in non-small cell lung cancer after checkpoint inhibitor failure; the trial received a second positive Independent Data Monitoring Committee recommendation in February 2026, and Tedopi showed positive phase 2 results in recurrent ovarian cancer (TEDOVA, ASCO 2026). OSE-279 is an anti-PD-1 antibody, with partnered programmes ABBV-230 (AbbVie) and BI 770371 (Boehringer Ingelheim). Outside oncology, lusvertikimab (anti-IL-7R) targets inflammatory bowel disease and pegrizeprument is partnered with Veloxis in transplantation. In May 2026 OSE signed a flexible bridge equity financing with IRIS Capital for up to about EUR 19.3 million, extending cash runway to December 2026.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Nantes
- Type: biotech
- Website: https://www.ose-immuno.com
- Ticker: OSE.PA

## Notes

- Founding year not sourced.

## Sources

- Official website: https://www.ose-immuno.com
- Press releases: https://www.ose-immuno.com/en/press-releases/
- Bridge equity financing with IRIS (May 2026): https://www.ose-immuno.com/wp-content/uploads/2026/05/OSE-PR_EN_260528_IRIS-Financing-vdef.pdf

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [OSE2101](https://onco.cc/drugs/ose2101/)
- trials: [Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas](https://onco.cc/trials/nct05751798/), [Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor](https://onco.cc/trials/nct06472245/)

---
JSON: https://onco.cc/api/v1/entities/ose-immunotherapeutics.json